获取途径

作者

Donghui Liu, Qian Li, Shu Yan, Xinyue Zhang, Weiqiang Li, Feiyu Wang, Lei Gao, Fei Geng, Haiyan Zhou, Panpan Ye, Furong Zhao, Weizhe Xue, Peilong Zhang, Xingxing Diao, Wei Zhao

作者单位

Affiliations ¹ School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China. ² Shanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China. ³ Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, 250014, China. ⁴ Beijing Avistone Biotechnology Co., Ltd, Beijing, 100102, China. ⁵ School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China. xxdiao@simm.ac.cn. ⁶ Shanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China. xxdiao@simm.ac.cn. ⁷ XenoFinder Co., Ltd, Suzhou, 215123, China. xxdiao@simm.ac.cn. ⁸ Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, 250014, China. zhao4wei2@hotmail.com.

刊名

Cancer chemotherapy and pharmacology

年份

2025

卷号

Vol.95 No.1

页码

19

ISSN

1432-0843

关键词

EGFR-TKI Mass balance PLB1004 Radioactivity [14C]PLB1004.

摘要

Purpose: PLB1004, developed by Beijing Avistone Biotechnology Co., Ltd., is a safe, highly selective, and efficient irreversible epidermal growth factor receptor tyrosine kinase inhibitor employed in treating non-small-cell-lung-cancer . This study investigated its pharmacokinetics, mass balance, and metabolism in 6 healthy Chinese male subjects treated with 160 mg [C]PLB1004. Methods: Following drug administration, samples of blood, urine and feces were collected for quantitative determinatio...更多

Purpose: PLB1004, developed by Beijing Avistone Biotechnology Co., Ltd., is a safe, highly selective, and efficient irreversible epidermal growth factor receptor tyrosine kinase inhibitor employed in treating non-small-cell-lung-cancer . This study investigated its pharmacokinetics, mass balance, and metabolism in 6 healthy Chinese male subjects treated with 160 mg [C]PLB1004. Methods: Following drug administration, samples of blood, urine and feces were collected for quantitative determination of total radioactivity and metabolites were identified through radioactivity detection coupled with UHPLC-MS/MS. Results: Following drug administration, the median radioactive T was 4.17 h in plasma, with the average t of PLB1004-related components in plasma of approximately 54.3 h. Over 264 h post-administration, the average cumulative excretion among the six subjects was 95.01% of the administered dose, with 84.71% and 10.30% excreted in feces and urine, respectively. Nine metabolites were characterized and identified and the parent drug PLB1004 was detected in plasma, urine, and feces. Among these metabolites, M689 was the most prevalent one in plasma, urine, and feces, constituting 25.37% of the total plasma radioactivity, and 55.88% and 1.73% of the administrated dose in feces and urine, respectively. Conclusion: Fecal excretion emerged as PLB1004 excretion route, while urinary excretion via the kidneys served as the secondary route. The primarily metabolic pathways are oxidation, demethylation, dehydrogenation, and cysteine conjugation in humans.收起

文献类型

期刊